Pasireotide (SOM230): Development, mechanism of action and potential applications

Cited by (256)

Items 101–200 of 256

1. Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1–Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression
   G. Walls, M. Stevenson, B. Soukup, K. Lines, A. Grossman, H. Schmid, R. Thakker · 2016 · Endocrinology
2. Pasireotide for the treatment of acromegaly
   L. Wildemberg, M. Gadelha · 2016 · Expert Opinion on Pharmacotherapy
3. Unusual complication of a pancreatic neuroendocrine tumor presenting with malignant hypercalcemia.
   G. Kanakis, G. Kaltsas, D. Granberg, Lars Grimelius, D. Papaioannou, A. Tsolakis, K. Öberg · 2012 · Journal of Clinical Endocrinology and Metabolism
4. Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study
   M. Pavel, F. Borson-Chazot, A. Cailleux, D. Hörsch, H. Lahner, R. Pivonello, L. Tauchmanovà, C. Darstein, H. Olsson, F. Tiberg et al. · 2018 · Cancer Chemotherapy and Pharmacology
5. Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors.
   J. Molina-Cerrillo, T. Alonso-Gordoa, O. Martínez-Sáez, E. Grande · 2016 · The Oncologist
6. Extremophilic proteases as novel and efficient tools in short peptide synthesis
   A. Białkowska, K. Morawski, T. Florczak · 2017 · Journal of Industrial Microbiology & Biotechnology
7. Paraneoplastic Cushing syndrome, case-series and review of the literature
   Annelies Deldycke, C. Haenebalcke, Y. Taes · 2018 · Acta Clinica Belgica
8. Somatostatin analogs and chimeric somatostatin-dopamine molecules differentially regulate human growth hormone and prolactin gene expression and secretion in vitro.
   A. Gruszka, M. Culler, S. Melmed · 2012 · Molecular and Cellular Endocrinology
9. Absence of somatostatin SST2 receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model
   Beatrice Waser, Renzo Cescato, Maria‐Luisa Tamma, Helmut R. Maëcke, Jean Claude Reubi · 2010 · European Journal of Pharmacology
10. Endocrine hypertension — Current understanding and comprehensive management review
    Norlela Sukor · 2011 · European Journal of Internal Medicine
11. Co-expression of somatostatin receptor subtypes and estrogen receptor-α mRNAs by non-functioning pituitary adenomas in young patients.
    H. Nishioka, K. Tamura, Haruka Iida, M. Kutsukake, A. Endo, Y. Ikeda, J. Haraoka · 2011 · Molecular and Cellular Endocrinology
12. Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro
    T. Graillon, D. Romano, Céline Défilles, Christophe Lisbonis, A. Saveanu, D. Figarella-Branger, P. Roche, S. Fuentès, O. Chinot, H. Dufour et al. · 2017 · OncoTarget
13. Novel Somatostatin Receptor Ligands Therapies for Acromegaly
    R. Paragliola, R. Salvatori · 2018 · Frontiers in Endocrinology
14. Pasireotide for the treatment of Cushing's disease
    Giorgio Arnaldi, Marco Boscaro · 2010 · Expert Opinion on Investigational Drugs
15. Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly
    Sabina Ruiz, J. Gil, B. Biagetti, E. Venegas, R. Cámara, Rogelio García-Centeno, M. Gálvez, A. Picó, Silvia Maraver, I. Gonzalez et al. · 2023 · Clinical Endocrinology
16. Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease
    M. Kugita, K. Nishii, Tamio Yamaguchi, A. Suzuki, Y. Yuzawa, S. Horie, E. Higashihara, S. Nagao · 2017 · PLoS ONE
17. [111In-DOTA]LTT-SS28, a First Pansomatostatin Radioligand for in Vivo Targeting of Somatostatin Receptor-Positive Tumors
    Θεοδοσία Μάινα, Renzo Cescato, Beatrice Waser, Aikaterini Tatsi, Aikaterini Kaloudi, Eric P. Krenning, Marion de Jong, Berthold A. Nock, Jean Claude Reubi · 2014 · Journal of Medicinal Chemistry
18. Targeting the somatostatin receptor in pituitary and neuroendocrine tumors
    Marije J. Veenstra, W. D. de Herder, R. Feelders, L. Hofland · 2013 · Expert opinion on therapeutic targets
19. Pasireotide (SOM230) protects the retina in animal models of ischemia induced retinopathies
    Despina Kokona, Niki Mastrodimou, Iosif Pediaditakis, Ioannis Charalampopoulos, HERBERT A. SCHMID, Kyriaki Thermos · 2012 · Experimental Eye Research
20. Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study
    C. Beglinger, K. Hu, Ying Wang, E. Bouillaud, C. Darstein, Yan-Feng Wang, P. Mohideen · 2012 · Endocrine
21. BILN: A Human-Readable Line Notation for Complex Peptides
    Thomas Fox, M. Bieler, P. Haebel, Rodrigo Ochoa, Stefan Peters, Alexander Weber · 2022 · Journal of Chemical Information and Modeling
22. Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors
    James C. Yao, J. Chan, A. Mita, M. Kundu, Karina Hermosillo Reséndiz, K. Hu, Shoba Ravichandran, J. Strosberg, E. Wolin · 2017 · OncoTargets and Therapy
23. Management of neuroendocrine tumors
    Clement Chung · 2016 · American Journal of Health-System Pharmacy
24. The clinical significance of somatostatin in pancreatic diseases.
    M. Śliwińska-Mossoń, M. Vesely, H. Milnerowicz · 2014 · Annales d'Endocrinologie
25. Involvement of bone morphogenetic protein activity in somatostatin actions on ovarian steroidogenesis.
    Eri Nakamura, F. Otsuka, K. Inagaki, Naoko Tsukamoto, K. Ogura-Ochi, T. Miyoshi, Kishio Toma, M. Takeda, H. Makino · 2013 · Journal of Steroid Biochemistry and Molecular Biology
26. Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms
    M. C. Cantone, A. Dicitore, G. Vitale · 2021 · Journal of Clinical Medicine
27. A Macrophage Membrane–Polymer Hybrid Biomimetic Nanoplatform for Therapeutic Delivery of Somatostatin Peptide to Chronic Pancreatitis
    Fang Wang, Yu Deng, Luying Yu, Ao Zhou, Jieting Wang, Jingyan Jia, Ning Li, Fadian Ding, Wei Lian, Qicai Liu et al. · 2022 · Pharmaceutics
28. Octreotide-Resistant Acromegaly: Challenges and Solutions
    G. Corica, M. Ceraudo, Claudia Campana, F. Nista, F. Cocchiara, M. Boschetti, G. Zona, Diego Criminelli, D. Ferone, F. Gatto · 2020 · Therapeutics and Clinical Risk Management
29. Structural modifications of amino acid sequences of radiolabeled peptides for targeted tumor imaging
    Fariba Maleki, Arezou Masteri Farahani, Farzaneh Rezazedeh, Nourollah Sadeghzadeh · 2020 · Bioorganic Chemistry
30. Pathophysiology of Gastric NETs: Role of Gastrin and Menin
    Sinju Sundaresan, Anthony J. Kang, Juanita L. Merchant · 2017 · Current Gastroenterology Reports
31. New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future
    E. U. Cidon · 2017 · World Journal of Gastrointestinal Oncology
32. Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors
    D. Castellano, E. Grande, J. Valle, J. Capdevila, D. Reidy-Lagunes, J. O'Connor, E. Raymond · 2015 · Cancer Chemotherapy and Pharmacology
33. The Neuropeptide Systems and their Potential Role in the Treatment of Mammalian Retinal Ischemia: A Developing Story
    Davide Cervia, G. Casini · 2013 · Current Neuropharmacology
34. Tolerability and dose proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study.
    S. Petersenn, K. Hu, M. Maldonado, Yilong Zhang, J. Lasher, E. Bouillaud, Yan-Feng Wang, K. Mann, N. Unger · 2012 · Clinical Therapeutics
35. Nelson syndrome: definition and management.
    Thomas M. Barber, E. Adams, J. A. Wass · 2014 · Handbook of Clinical Neurology
36. Progress in the Stereoselective Synthesis Methods of Pyrrolidine-Containing Drugs and Their Precursors
    Аndrey V. Smolobochkin, Almir Sabirovich Gazizov, Nurbol Orynbasaruly Appazov, Oleg Gerol'dovich Sinyashin, Alexander Romanovich Burilov · 2024 · International Journal of Molecular Sciences
37. The Effects of Peptide Receptor Radionuclide Therapy on the Neoplastic and Normal Pituitary
    P. Marques · 2023 · Cancers
38. Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer
    M. Thakur, L. Heilbrun, Kimberlee Dobson, J. Boerner, K. Stark, Jing Li, D. Smith, E. Heath, J. Fontana, U. Vaishampayan · 2018 · Clinical Genitourinary Cancer
39. Pasireotide does not improve efficacy of aspiration sclerotherapy in patients with large hepatic cysts, a randomized controlled trial
    T. Wijnands, T. Gevers, M. Lantinga, R. T. Te Morsche, L. Schultze Kool, J. Drenth · 2018 · European Radiology
40. Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data
    S. Samson · 2015 · Neuroendocrinology
41. Evolving Treatment Strategies for Management of Carcinoid Tumors
    Jonathan Strosberg · 2013 · Current Treatment Options in Oncology
42. New formulations and approaches in the medical treatment of acromegaly
    M. Debono, J. Newell-Price · 2010 · Current Opinion in Endocrinology, Diabetes & Obesity
43. Prognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle
    A. Berruti, F. Vignani, L. Russo, V. Bertaglia, Mattia Tullio, M. Tucci, M. Poggio, L. Dogliotti · 2010 · Open Access Journal of Urology
44. Current therapy and drug pipeline for the treatment of patients with acromegaly
    S. Kumar, J. Ayuk, R. Murray · 2009 · Advances in Therapy
45. Revisiting C.G. Moertel's land of small tumors.
    L. Kvols · 2008 · Journal of Clinical Oncology
46. Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
    R. Feelders, M. Fleseriu, P. Kadıoğlu, M. Bex, D. González-Devia, C. Boguszewski, Dilek Gogas Yavuz, Heather Patino, A. Pedroncelli, R. Maamari et al. · 2023 · Frontiers in Endocrinology
47. Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs
    G. Corica, R. Pirchio, A. Milioto, F. Nista, A. Arecco, L. Mattioli, R. Auriemma, F. Cocchiara, R. Pivonello, A. Colao et al. · 2023 · Journal of Endocrinological Investigation
48. Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors
    Kristen V. McClellan, Emerson Yu-sheng Chen, Adel Kardosh, Charles D. Lopez, Jaydira Del Rivero, Nadine Mallak, Flavio G. Rocha, Yilun Koethe, Rodney F. Pommier, Erik Mittra et al. · 2022 · Cancers
49. The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors
    Alexandria T. Phan, Bhuvanesh Dave · 2016 · Cancer Medicine
50. Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study.
    Xia Chen, Guo-Xiang Shen, Ji Jiang, Hong-Zhong Liu, K. Hu, C. Darstein, J. Lasher, P. Hu · 2014 · Clinical Therapeutics
51. Lower 68Ga‐DOTATOC uptake in nonfunctioning pituitary neuroendocrine tumours compared to normal pituitary gland—A proof‐of‐concept study
    Axel Tjörnstrand, Olivera Casar‐Borota, Kerstin Heurling, Michael Schöll, Peter Gjertsson, Jakob Himmelman, Oleksiy Itsenko, Óskar Ragnarsson, Helena Filipsson Nyström · 2019 · Clinical Endocrinology
52. Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models
    Taofeek Kunle Owonikoko, Guojing Zhang, Shenila B. Lallani, Zhengjia Chen, Deborah E. Martinson, Fadlo Raja Khuri, Sagar Lonial, Adam I. Marcus, Shi‐Yong Sun · 2019 · PLoS ONE
53. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.
    J. Chan, M. Kulke · 2016 · Surgical Oncology Clinics of North America
54. A systematic review of management of neuroendocrine tumors: An experience from a tertiary care centre from India
    R. Kapoor, T. Bhattacharyya, R. Gupta, B. Mittal, N. Kalra · 2014
55. Systemic Therapy for Advanced Pancreatic Neuroendocrine Tumors
    M. Kulke · 2013 · Seminars in Oncology
56. The Synergistic Effect of Pasireotide and Teriflunomide in Carcinoids in vitro
    Y. Somnay, Herb Chen, M. Kunnimalaiyaan · 2012 · Neuroendocrinology
57. Structural insights into somatostatin receptor 5 bound with cyclic peptides
    Ying-Ge Li, Xiang-Hui Meng, Xi-Ru Yang, Sheng-Long Ling, Pan Shi, Changlin Tian, Fan Yang · 2024 · Acta Pharmacologica Sinica
58. Outcomes of peri-operative glucocorticosteroid use in major pancreatic resections: a systematic review.
    Li-Lian Kuan, A. Dennison, G. Garcea · 2021 · HPB
59. Applications of peptide hormone ligands for the treatment of dumping and short bowel syndrome
    Lucas I. Wauters, Tim Vanuytsel · 2018 · Current Opinion in Pharmacology
60. When and How to Use Somatostatin Analogues.
    W. D. de Herder · 2018 · Endocrinology and metabolism clinics of North America (Print)
61. Treatment of a thyrotropin‐secreting pituitary adenoma (TSH‐oma) with pasireotide LAR
    Marlise E. A. van Eersel, Susanne H. Meeuwisse-Pasterkamp, A. Muller Kobold, L. Meiners, W. D. den Dunnen, L. Hofland, G. van den Berg · 2017 · Clinical Endocrinology
62. Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats
    E. Tarasco, Petra Seebeck, Svende Pfundstein, A. Daly, Philippe J. Eugster, A. Harris, E. Grouzmann, T. Lutz, C. Boyle · 2017 · Endocrine
63. Investigational therapies for acromegaly
    L. Grasso, R. Pivonello, A. Colao · 2013 · Expert Opinion on Investigational Drugs
64. Recent advances in the diagnosis and treatment of gastrointestinal carcinoids.
    Joe Valentino, B. M. Evers · 2011 · Advances in Surgery
65. Release kinetics of somatostatin from self‐assembled nanostructured hydrogels
    U. Rai, T. Thrimawithana, D. Dharmadana, C. Valéry, S. Young · 2018 · Biopolymers
66. A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers
    G. Golor, K. Hu, M. Ruffin, A. Buchelt, E. Bouillaud, Yan-Feng Wang, M. Maldonado · 2012 · Drug Design, Development and Therapy
67. Effect of Hepatic Impairment on the Pharmacokinetics of Pasireotide (SOM230): Results From a Multicenter Phase I Study
    Y. Horsmans, K. Hu, M. Ruffin, Ying Wang, D. Song, E. Bouillaud, Yan-Feng Wang, D. Mazur, F. Botha, D. Heuman · 2012 · Journal of clinical pharmacology
68. Optimizing acromegaly treatment.
    M. Bronstein · 2010 · Frontiers of Hormone Research
69. Somatostatin analogue pasireotide (SOM230) inhibits catecholamine secretion in human pheochromocytoma cells.
    L. Streit, S. Moog, S. Hugel, Marion Rame, Émeline Tanguy, V. Andry, H. Schmid, L. Brunaud, F. Bihain, C. Nominé-Criqui et al. · 2021 · Cancer Letters
70. Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review.
    S. Pusceddu, F. De Braud, F. Festinese, Cristina Bregant, A. Lorenzoni, M. Maccauro, M. Milione, L. Concas, B. Formisano, Livia Leuzzi et al. · 2015 · Future Oncology
71. The Effect of Albumin Fusion Patterns on the Production and Bioactivity of the Somatostatin-14 Fusion Protein in Pichia pastoris
    Yue-Di Ding, Jun Fan, Wenxin Li, Run-Lin Yang, Ying Peng, L. Deng, Yu Wu, Qiang Fu · 2013 · Applied Biochemistry and Biotechnology
72. Zoledronic acid but not somatostatin analogs exerts anti‐tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration‐resistant prostate cancer
    K. Hashimoto, N. Masumori, Toshiaki Tanaka, Toshihiro Maeda, K. Kobayashi, H. Kitamura, K. Hirata, T. Tsukamoto · 2013 · The Prostate
73. Update on the management of neuroendocrine tumors: focus on somatostatin antitumor effects.
    Nancy M Gardner-Roehnelt · 2012 · Clinical Journal of Oncology Nursing
74. Preclinical evidences suggest new treatment options for endocrine disorders: Pasireotide (SOM230) and Everolimus (RAD001).
    H. Schmid · 2008 · Annales d'Endocrinologie
75. VX‐809 mitigates disease in a mouse model of autosomal dominant polycystic kidney disease bearing the R3277C human mutation
    Murali K. Yanda, Liudmila Cebotaru · 2021 · The FASEB Journal
76. The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors
    Eleonora Vitali, Sara Piccini, Giampaolo Trivellin, Valeria Smiroldo, Elisabetta Lavezzi, Alessandro Zerbi, Giovanna Pepe, Andrea Gerardo Lania · 2021 · Molecular and Cellular Endocrinology
77. The position of combined medical treatment in acromegaly
    Eva C. Coopmans, S. V. van Meyel, A. J. van der Lely, S. Neggers · 2019 · Archives of Endocrinology and Metabolism
78. Is receptor profiling useful for predicting pituitary therapy?
    M. Marazuela, A. Ramos-Leví, Patricia Borges de Souza, M. Zatelli · 2018 · European Journal of Endocrinology
79. New Treatments for the Carcinoid Syndrome.
    P. Loughrey, Dongyun Zhang, A. Heaney · 2018 · Endocrinology and metabolism clinics of North America (Print)
80. Somatostatin analogs, cabergoline and pegvisomant: comparing the efficacy of medical treatment for acromegaly
    L. Grasso, R. Auriemma, R. Pivonello, A. Colao · 2017 · Expert Review of Endocrinology & Metabolism
81. Octreotide long-acting repeatable for acromegaly
    Renato Cesare Cozzi, Roberto Attanasio · 2012 · Expert Review of Clinical Pharmacology
82. Management of neuroendocrine tumors: current and future therapies
    Kjell E. Öberg · 2010 · Expert Review of Endocrinology & Metabolism
83. New treatment guidelines on Cushing's disease
    Giorgio Arnaldi, Marco Boscaro · 2009 · F1000 Medicine Reports
84. Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center
    R. Pirchio, R. Auriemma, A. Vergura, R. Pivonello, A. Colao · 2024 · Journal of Endocrinological Investigation
85. Rapid response of Nelson’s syndrome to pasireotide in radiotherapy-naive patient
    Xin He, Joanna L. Spencer-Segal · 2020 · Clinical Diabetes and Endocrinology
86. Somatostatin Agonist Pasireotide Inhibits Exercise‐Stimulated Growth in the Male Siberian Hamster (Phodopus sungorus)
    Rebecca Dumbell, Ines Petri, Frank Scherbarth, Victoria Diedrich, HERBERT A. SCHMID, Stephan Steinlechner, Perry Barrett · 2016 · Journal of Neuroendocrinology
87. Aspiration sclerotherapy combined with pasireotide to improve reduction of large symptomatic hepatic cysts (SCLEROCYST): study protocol for a randomized controlled trial
    T. Wijnands, T. Gevers, L. Schultze Kool, J. Drenth · 2015 · Trials
88. The effect of albumin fusion structure on the production and bioactivity of the somatostatin-28 fusion protein in Pichia pastoris
    Yue-Di Ding, Jun Fan, Wenxin Li, Ying Peng, Run-Lin Yang, L. Deng, Qiang Fu · 2014 · Journal of Industrial Microbiology & Biotechnology
89. Application of triple quadrupole tandem mass spectrometry to the bioanalysis of collision-induced dissociation-resistant cyclic peptides - Ultra-sensitive quantification of the somatostatin-analog pasireotide utilizing UHPLC-MS/MS.
    M. Sauter, Philipp Uhl, J. Burhenne, W. Haefeli · 2020 · Journal of Pharmaceutical and Biomedical Analysis
90. Update on management of midgut neuroendocrine tumors
    Amir Mehrvarz Sarshekeh, D. Halperin, A. Dasari · 2016 · International Journal of Endocrine Oncology
91. Pasireotide (SOM230): a novel pituitary-targeted medical therapy for the treatment of patients with Cushing’s disease
    Kelley J. Moloney, Jennifer U. Mercado, W. Ludlam, M. Mayberg · 2012 · Expert Review of Endocrinology & Metabolism
92. Neuroendokrine Tumoren des Gastrointestinaltraktes
    J. Bornschein, Mark Kidd, P. Malfertheiner, I. M. Modlin · 2008 · Deutsche Medizinische Wochenschrift
93. Pasireotide-induced hyperglycemia in Cushing’s disease and Acromegaly: A clinical perspective and algorithms proposal
    Przemysław Witek, Marek Bolanowski, Adam Jacek Kretowski, Aleksandra Głowińska · 2024 · Frontiers in Endocrinology
94. Resistance of neuroendocrine tumours to somatostatin analogs
    A. Angelousi, A. Koumarianou, Eleftherios Chatzellis, G. Kaltsas · 2023 · Expert Review of Endocrinology & Metabolism
95. A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer
    J. Bauman, Zheng-Jia Chen, Chao Zhang, J. Ohr, R. Ferris, Gerald M. McGorisk, S. Brandt, S. Srivatsa, Amy Y. Chen, C. Steuer et al. · 2022 · Cancers
96. A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting
    Rosalba Mansi, Karim Abid, Guillaume P. Nicolas, Luigi Del Pozzo, Eric Grouzmann, Melpomeni Fani · 2020 · EJNMMI Research
97. SOMATOSTATIN ANALOGUES FOR THE TREATMENT OF NEUROENDOCRINE TUMOURS. DOSAGE FORMS AND ROUTES OF ADMINISTRATION (REVIEW)
    Z. Shprakh · 2020 · International Journal of Applied Pharmaceutics
98. Diagnostic accuracy of technetium-99m-octreotide in imaging neuroendocrine tumors, Oman hospital experience with literature review
    Naima Al Bulushi, Badriya Al-Suqri, Marwa Al Aamri, Aymen M. Al-Hadidi, Hafidh Al Jahdami, M. Al Zadjali, Mimouna Al Risi · 2019 · World Journal of Nuclear Medicine
99. Synthesis and binding affinities for sst receptors of cyclic peptoid SRIF-mimetics
    C. Caumes, Thomas Hjelmgaard, O. Roy, M. Reynaud, D. Servent, C. Taillefumier, S. Faure · 2012
100. Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs)
     E. Grande, J. Díez, V. Pachón, A. Carrato · 2010 · Clinical and Translational Oncology